Abstract: The present invention relates to a method of determining the subtype of a pancreatic ductal adenocarcinoma patient through proteogenomic analysis of PDAC. The method of determining the subtype of pancreatic cancer according to one embodiment of the present invention comprises steps of: (1) pulverizing a pancreatic ductal adenocarcinoma lesion tissue isolated from a pancreatic ductal adenocarcinoma patient; (2) obtaining a peptide sample for the patient by extracting and digesting proteins from the lesion tissue; (3) measuring the expression levels of representative genes of pancreatic ductal adenocarcinoma subtypes 1 to 6 from the peptide sample for the patient; and (4) determining the subtype of the pancreatic ductal adenocarcinoma patient by comparing the expression levels of the representative genes of pancreatic ductal adenocarcinoma subtypes 1 to 6.

Abstract: Provided are a composition or a kit for diagnosing colorectal cancer including a CXCL7-measuring agent, and a method of diagnosing colorectal cancer using the same. According to the composition or the kit, and the method, colorectal cancer may be simply diagnosed with high diagnostic accuracy and specificity for colorectal cancer.

Abstract: A biomarker for diagnosing age-related macular degeneration includes a vinculin protein, and a diagnostic kit, a diagnostic method, and a method of screening a therapeutic material for age-related macular degeneration use the biomarker. The diagnostic kit and the diagnostic method of age-related macular degeneration are novel immunological diagnostic tools using the plasma of a patient, and have remarkable sensitivity that enables simple analysis of plasma without a biopsy, and thus can be useful for diagnosing age-related macular degeneration.

Abstract: Disclosed are novel imidazolylalkylcarbonyl derivatives useful as calcium channel modulators and a preparation method of the same. Also disclosed is a method for the treatment of diseases by administering the above compounds based on their inhibitory activity against calcium channel.

Abstract: The present invention relates to a thermostable alpha-1-antitrypsin mutein with a disulfide bond and a preparation method of the same, more precisely an alpha-1-antitrypsin mutein with improved thermostability, compared with the conventional thermostable alpha-1-antitrypsin mutein (Korean Patent No. 133252), resulted from the process of substituting the 168th and 189th amino acids of the alpha-1-antitrypsin with cysteines which are then linked by a disulfide bond, with keeping its alpha-1-antitrypsin activity unchanged, and a preparing method of the same. The thermostable alpha-1-antitrypsin mutein with a disulfide bond of the invention can be effectively used for a protein based therapeutic agent which is very stable in vivo, and can be applied further in various fields including in the development of a diagnostic reagent and in the preparation of an affinity column.

Abstract: The present invention relates to a thermostable alpha-1-antitrypsin mutein with a disulfide bond and a preparation method of the same, more precisely an alpha-1-antitrypsin mutein with improved thermostability, compared with the conventional thermostable alpha-1-antitrypsin mutein (Korean Patent No. 133252), resulted from the process of substituting the 168th and 189th amino acids of the alpha-1-antitrypsin with cysteines which are then linked by a disulfide bond, with keeping its alpha-1-antitrypsin activity unchanged, and a preparing method of the same. The thermostable alpha-1-antitrypsin mutein with a disulfide bond of the invention can be effectively used for a protein based therapeutic agent which is very stable in vivo, and can be applied further in various fields including in the development of a diagnostic reagent and in the preparation of an affinity column.

Abstract: Disclosed are isoindolinone derivatives, represented by Chemical Formula 1, having inhibitory activity against T-type calcium channels, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient. wherein R1˜R6 are as defined in the specification.

Abstract: Disclosed are novel imidazolylalkylcarbonyl derivatives useful as calcium channel modulators and a preparation method of the same. Also disclosed is a method for the treatment of diseases by administering the above compounds based on their inhibitory activity against calcium channel.